HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing

Title
HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing
Author(s)
배영경신형찬김애리박석주
Keywords
IN-SITU HYBRIDIZATION; COPY NUMBER; AMERICAN-SOCIETY; GENE STATUS; CANCER; RECEPTOR; RECOMMENDATIONS; POLYSOMY
Issue Date
201112
Publisher
KOREAN SOCIETY PATHOLOGISTS
Citation
KOREAN JOURNAL OF PATHOLOGY, v.45, no.6, pp.665 - 669
Abstract
Recently we experienced three cases of human epidermal growth factor receptor 2 (HER2)-amplified invasive breast carcinomas associated with co-amplification or gain of chromosome 17 centromere (CEP17) in silver-enhanced in situ hybridization (SISH) analysis. These cases revealed 2+ or 3+ staining for HER2 immunohistochemistry and > 6 HER2 copies per cell on SISH analyses. However, the calculated HER2/CEP17 ratios were low (< 2.2) and did not fit within the HER2-positive category. We interpreted those cases as HER2-positive tumors based on the number of HER2 copies per cell. There is a potential for misinterpretation of SISH analysis in cases showing increased CEP17 copy number, based on the criterion used for HER2 positivity (HER2 copies > 6 per cell vs HER2/CEP17 ratio > 2.2). We recommend reporting raw SISH or fluorescence in situ hybridization data, including number of cells counted, average numbers of HER2 and CEP17 signals, and the calculated HER2/CEP17 ratio to prevent underreporting of HER2 amplification.
URI
http://hdl.handle.net/YU.REPOSITORY/24209http://dx.doi.org/10.4132/KoreanJPathol.2011.45.6.665
ISSN
1738-1843
Appears in Collections:
의과대학 > 병리학교실 > Articles
의과대학 > 영상의학과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE